Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone224-667-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.58 billion
Profitability
Miscellaneous
Employees99,000
OptionableOptionable
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, December 14th. Investors of record on Tuesday, January 15th will be paid a dividend of $0.32 per share on Friday, February 15th. This represents a $1.28 annualized dividend and a dividend yield of 1.70%. The ex-dividend date is Monday, January 14th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.28. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) released its earnings results on Wednesday, January, 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.81. The healthcare product maker earned $7.77 billion during the quarter, compared to analyst estimates of $7.82 billion. Abbott Laboratories had a return on equity of 16.50% and a net margin of 7.74%. Abbott Laboratories's quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.74 earnings per share. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its FY19 earnings guidance on Wednesday, January, 23rd. The company provided earnings per share (EPS) guidance of $3.15-3.25 for the period, compared to the Thomson Reuters consensus estimate of $3.20. Abbott Laboratories also updated its FY 2019 guidance to $3.15-3.25 EPS.
What price target have analysts set for ABT?
18 analysts have issued twelve-month target prices for Abbott Laboratories' shares. Their forecasts range from $68.00 to $90.00. On average, they anticipate Abbott Laboratories' share price to reach $79.4438 in the next year. This suggests a possible upside of 5.6% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
What are Wall Street analysts saying about Abbott Laboratories stock?
Here are some recent quotes from research analysts about Abbott Laboratories stock:
- 1. According to Zacks Investment Research, "Abbott exited the fourth quarter on a mixed note with earnings in line with the Zacks Consensus Estimate and revenues missing the mark. Increasing currency headwinds to some extent dented the company’s international performance. Meanwhile, emerging market performance has been promising. We are optimistic about the strong and consistent performance by the company’s EPD and Medical Devices segments organically. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip improves further following the FDA approval of its upgraded version. This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Vascular arm in the United States continues to dent growth. Overall, Abbott has been outperforming its industry over the past three months." (1/28/2019)
- 2. BTIG Research analysts commented, "Q4 was a mixed bag with reported revenue and margin falling short of consensus’ expectations, mostly due to f/x. Organic revenue growth was 6.4%, sequentially slower on the surface. However, ABT overcame its toughest comp in Q4 but smoothed for comps, revenue growth continued its upward trajectory. Importantly, ABT’s initial FY19 revenue outlook of 6.5-7.5% came in slightly ahead of our forecast. We think there is still a good chance 1.0/2.0 can nudge this range higher. Management noted that hitting the FY19 revenue range is not predicated on either a meaningful ramp in MitraClip or Libre 2.0 rollout in the U.S. The company also suggested that tweaks to underperforming areas like Neuromod should easily drive performance to the higher end of the range. Overall, we see little risk to the ABT story but see the valuation of 22x NTM EPS as appropriate." (1/24/2019)
Has Abbott Laboratories been receiving favorable news coverage?
Headlines about ABT stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the healthcare product maker a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 64)
- Mr. Robert B. Ford, Pres & COO (Age 45)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 40)
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.89%), Massachusetts Financial Services Co. MA (1.92%), Oregon Public Employees Retirement Fund (1.71%), Northern Trust Corp (1.51%), Bank of New York Mellon Corp (1.39%) and Geode Capital Management LLC (1.26%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which institutional investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Prudential Financial Inc., Bank of New York Mellon Corp, Canada Pension Plan Investment Board, Diamond Hill Capital Management Inc., Lord Abbett & CO. LLC, Flossbach Von Storch AG and Retirement Systems of Alabama. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which institutional investors are buying Abbott Laboratories stock?
ABT stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Sustainable Growth Advisers LP, Geode Capital Management LLC, Epoch Investment Partners Inc., GQG Partners LLC, Eaton Vance Management and Bahl & Gaynor Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks and John G Stratton. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $75.25.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $132.16 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
What is Abbott Laboratories' official website?
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
